SGLT2 Inhibitors for Cardioprotection.
作者信息
Al Rashid Sulthan, Elango P, Rahman Syed Ziaur
机构信息
Department of Pharmacology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
Department of Pharmacology, Bhaarath Medical College and Hospital, Bharath Institute of Higher Education and Research, Chennai, India.
出版信息
Oman Med J. 2023 Jul 31;38(4):e521. doi: 10.5001/omj.2023.128. eCollection 2023 Jul.
Abstract
摘要
相似文献
1
SGLT2 Inhibitors for Cardioprotection.用于心脏保护的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂
Oman Med J. 2023 Jul 31;38(4):e521. doi: 10.5001/omj.2023.128. eCollection 2023 Jul.
2
Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.钠-葡萄糖协同转运蛋白2抑制剂对动脉粥样硬化的影响：来自2型糖尿病患者心血管临床结局及基础研究的经验教训
J Clin Med. 2021 Dec 27;11(1):137. doi: 10.3390/jcm11010137.
3
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.SGLT2 抑制剂与心脏保护：争议与多种假说并存。
Postgrad Med. 2019 Mar;131(2):82-88. doi: 10.1080/00325481.2019.1581971.
4
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭中的作用机制及其临床价值
J Cardiovasc Pharmacol. 2023 Jan 1;81(1):4-14. doi: 10.1097/FJC.0000000000001380.
5
Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress.对钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂降低心力衰竭事件发生风险的潜在机制进行批判性审视：确定其刺激红细胞增多作用与减轻细胞应激作用之间的分子联系。
Cardiovasc Res. 2021 Jan 1;117(1):74-84. doi: 10.1093/cvr/cvaa064.
6
Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.钠-葡萄糖共转运蛋白 2 抑制剂的心脏保护作用：从肾脏近端小管的角度来看。
Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C328-C336. doi: 10.1152/ajpcell.00275.2019. Epub 2019 Nov 13.
7
Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure.钠-葡萄糖协同转运蛋白 2 抑制剂对心力衰竭相关离子稳态和氧化应激机制的影响。
Biomed Pharmacother. 2021 Nov;143:112169. doi: 10.1016/j.biopha.2021.112169. Epub 2021 Sep 22.
8
The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells.SGLT2 抑制剂对肾 MDCK 和 HK-2 细胞中 αKlotho 的影响。
Front Endocrinol (Lausanne). 2023 Mar 8;14:1069715. doi: 10.3389/fendo.2023.1069715. eCollection 2023.
9
Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂可减少心肌缺血再灌注损伤的临床前动物模型中的心肌梗死面积：一项荟萃分析。
Diabetologia. 2021 Apr;64(4):737-748. doi: 10.1007/s00125-020-05359-2. Epub 2021 Jan 23.
10
Renoprotection with sodium-glucose cotransporter-2 inhibitors in children: Knowns and unknowns.钠-葡萄糖共转运蛋白 2 抑制剂在儿童中的肾脏保护作用：已知与未知。
Nephrology (Carlton). 2022 Feb;27(2):126-132. doi: 10.1111/nep.13979. Epub 2021 Sep 26.
本文引用的文献
1
Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病合并高血压患者血压控制的疗效和安全性评估：一项新的荟萃分析
Diabetol Metab Syndr. 2023 Jun 7;15(1):118. doi: 10.1186/s13098-023-01092-z.
2
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.美国临床内分泌学会临床实践指南：制定糖尿病综合护理计划-2022 更新版。
Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002. Epub 2022 Aug 11.
3
Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.钠-葡萄糖协同转运蛋白 2 抑制剂在心力衰竭中的心脏获益机制：潜在非靶效应的证据。
J Mol Cell Cardiol. 2022 Jun;167:17-31. doi: 10.1016/j.yjmcc.2022.03.005. Epub 2022 Mar 22.
4
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure.钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭中的酮代谢
J Lipid Atheroscler. 2022 Jan;11(1):1-19. doi: 10.12997/jla.2022.11.1.1. Epub 2022 Jan 13.
5
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.血管紧张素 II 诱导的 SGLT1 和 2 上调促进人微小颗粒刺激的内皮衰老和功能障碍：格列净的保护作用。
Cardiovasc Diabetol. 2021 Mar 16;20(1):65. doi: 10.1186/s12933-021-01252-3.
6
Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.钠-葡萄糖协同转运蛋白 2 抑制剂通过减少自噬对心肌梗死的心脏保护作用机制。
Protein Cell. 2022 May;13(5):336-359. doi: 10.1007/s13238-020-00809-4. Epub 2021 Jan 8.
7
The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies.SGLT2 抑制剂联合 ACEI/ARB 治疗 2 型糖尿病的疗效和安全性：一项随机对照研究的荟萃分析。
Expert Opin Drug Saf. 2020 Nov;19(11):1497-1504. doi: 10.1080/14740338.2020.1817378. Epub 2020 Sep 3.
8
SGLT2i: beyond the glucose-lowering effect.SGLT2i：超越降糖作用。
Cardiovasc Diabetol. 2020 Jun 26;19(1):98. doi: 10.1186/s12933-020-01071-y.
9
Empagliflozin restores the integrity of the endothelial glycocalyx in vitro.恩格列净在体外恢复了内皮糖萼的完整性。
Mol Cell Biochem. 2019 Sep;459(1-2):121-130. doi: 10.1007/s11010-019-03555-2. Epub 2019 May 24.
10
Hypertension in patients with type 2 diabetes mellitus: Targets and management.2 型糖尿病患者的高血压：目标与管理。
Maturitas. 2018 Jun;112:71-77. doi: 10.1016/j.maturitas.2018.03.013. Epub 2018 Mar 30.
Zotero 插件